The new metric in prostate cancer prognosis
The Prolaris report provides you and your patient with a comprehensive analysis of their individual cancer aggressiveness as well as a clinically validated prognosis of their long-term risk of biochemical recurrence following radical prostatectomy. The report itself is designed to provide quick, easy to understand and clinically actionable information that can assist you in disease management decisions and patient counseling.
- The Prolaris Molecular Score is calculated by measuring the expression of cell cycle progression genes in the tumor. This shows how aggressive the individual tumor is, while the relative risk shows how the patient’s Prolaris Molecular Score compares to the average score in the patient’s NCCN risk category. The majority of Prolaris Scores will fall between 0 and 10 ^1,2 with a higher score indicating more aggressive cancer. For every one unit increase in the Prolaris Score, the patient’s mortality risk doubles.
- Clinical Variables and the Prolaris Molecular Score are used to calculate a patient’s risk assessment.
- For considering active surveillance, the 10-year disease specific mortality (DSM) risk with conservative management is shown to be within or beyond the Active Surveillance Threshold. Patients with a DSM within the gray (threshold) box may be considered appropriate for conservative management.
- For considering primary radiation therapy or radical prostatectomy, the 10-year risk of developing metastasis following definitive treatment is provided.
The patient’s disease-specific mortality (DSM) risk is represented with a “person” icon. This person is compared to other patients with prostate cancer in the same NCCN risk category. The average DSM risk of each NCCN risk category is shown with a triangle. The Active Surveillance Threshold is shown as a gray box.